AEterna Zentaris Revenue Growth: 66.08%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AEZS Revenue Growth Rankings
| Overall | 93rd percentile | 299 of 4424 |
| Sector | 87th percentile | 56 of 464 in Healthcare |
| Industry | 77th percentile | 28 of 127 in Biotechnology |
AEZS Revenue Growth Range, Past 5 Years
| Minimum | -82.58% | Dec 2006 |
| Maximum | 787.71% | Mar 2002 |
| Average | 128.91% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AEZS related companies
AEZS News
Aeterna Zentaris (AEZS) Updates on AEZS-108 Phase 1/2; Low Does Still Show Some Antitumor Acticity
Feb 03, 7:40AM Street Insider
Feb 03, 7:40AM Street Insider
$AEZS http://stks.co/2Axt Breaking out the Triangle...bullish momentum, looking for retest
about 12 days ago by gantosj
about 12 days ago by gantosj
Biotechnology Industry on the Upswing -- Aeterna Zentaris and Elite Pharmaceuticals to Benefit
Jan 25, 8:20AM Marketwire
Jan 25, 8:20AM Marketwire
$KERX $AEZS move lower after announcing at the market stock issuance program $$
about 19 days ago by peterumble
about 19 days ago by peterumble
Aeterna Zentaris (AEZS) Announces New At-the-Market Sales Agreement of Up 10.4 Million Shares
Jan 24, 10:08AM Street Insider
Jan 24, 10:08AM Street Insider
$AEZS http://stks.co/1zby Breaking out the triangle, positive divergence & Momentum
about 24 days ago by gantosj
about 24 days ago by gantosj
$AEZS http://stks.co/1tan Very close to the upper triangle line, breaking out & moving above $1.82 will give a huge run
about 31 days ago by gantosj
about 31 days ago by gantosj
Trying again, big wall at 1.80. Maybe fourth time is a charm. $AEZS http://chart.ly/6vgui7s
about 32 days ago by Wiserguy1971
about 32 days ago by Wiserguy1971
$AEZS Pull back 2-50 dma on lite volume,imho perfect point 2 start position in a great little bio. http://stks.co/1rIc http://stks.co/1rId
about 33 days ago by Wiserguy1971
about 33 days ago by Wiserguy1971
My favorite biospec. Beware of Phase III perifosine data out early 2102 ($KERX) but lots of goodies $AEZS http://chart.ly/35skdey
about 35 days ago by Wiserguy1971
about 35 days ago by Wiserguy1971
$AEZS http://stks.co/1or8 Chart for @wiserguy1971 Kumo break-out above 1.67, slight channel up
about 36 days ago by Tr8r_x
about 36 days ago by Tr8r_x
RT @GantosJ $AEZS $1.63 up 2.52% breaking out the 50MA after 3 weeks of consolidation///need larger volume for long runup though
about 37 days ago by boardroom
about 37 days ago by boardroom
Aeterna Zentaris (AEZS) Enters Collaboration with Ventana Medical for LHRH Development
Jan 05, 7:32AM Street Insider
Jan 05, 7:32AM Street Insider
A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)
Dec 14, 9:00AM Marketwire
Dec 14, 9:00AM Marketwire
Keryx Biopharma (KERX) Reports Strong Phase 2 Data for Perifosine w/ Sorafenib in Certain HL Patients
Dec 13, 8:28AM Street Insider
Dec 13, 8:28AM Street Insider
Aeterna Zentaris says data for perifosine in Hodgkin Lymphoma presented
Dec 13, 8:19AM theflyonthewall.com
Dec 13, 8:19AM theflyonthewall.com
ASH Meeting: $AEZS Encouraging preclinical data for oral anti-cancer treatment of Hodgkins Lymphoma. http://stks.co/1UmK
about 62 days ago by abubnic
about 62 days ago by abubnic
Aeterna Zentaris reports encouraging preclinical data for Perifosine in HL
Dec 12, 8:10AM theflyonthewall.com
Dec 12, 8:10AM theflyonthewall.com
Aeterna Zentaris (AEZS) Reports Strong Early Data for Perifosine in Hodgkin Lymphoma
Dec 12, 8:08AM Street Insider
Dec 12, 8:08AM Street Insider
Aeterna Zentaris presents positive preclinical breast cancer data on AEZS-131
Dec 09, 7:39AM theflyonthewall.com
Dec 09, 7:39AM theflyonthewall.com
Aeterna Zentaris (AEZS) Reports Positive Preclinical Data for Erk 1/2 Inhibitor, AEZS-131
Dec 09, 7:32AM Street Insider
Dec 09, 7:32AM Street Insider
$AEZS sold 1/2 into this strength this morning 1.83...waiting on other half
about 66 days ago by stevepotters2
about 66 days ago by stevepotters2
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AEZS | 1.64 | -0.06 | -3.53% | 159.23M |
| BCSI | 25.80 | 0.03 | 0.12% | 1.09B |
| ELNK | 7.94 | -0.09 | -1.12% | 855.77M |
| CTIC | 1.08 | -0.02 | -1.82% | 208.31M |
| NETL | 49.75 | -0.01 | -0.02% | 3.45B |
| BIDU | 136.59 | 1.15 | 0.85% | 37.00B |
| SWHC | 5.16 | -0.10 | -1.90% | 333.39M |
| RATE | 24.31 | 0.21 | 0.87% | 2.43B |
| UBOH | 8.00 | -0.25 | -3.02% | 27.52M |
| CLWR | 2.08 | 0.09 | 4.52% | 1.90B |
